Cytosorbents (CTSO) Other Operating Expenses (2010 - 2026)

Cytosorbents (CTSO) has reported Other Operating Expenses for 17 consecutive years, with -$30000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Operating Expenses changed N/A year-over-year to -$30000.0; the trailing twelve-month figure through Jun 2026 stood at $7.4 million (up 137.79% YoY), and the FY2024 full-year result was -$25.9 million, down 1.65% from the prior year.
• Other Operating Expenses rose to -$30000.0 in Q2 2026 per CTSO's latest filing, from -$6.6 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $20.9 million in Q4 2025 and bottomed at -$6.9 million in Q1 2024.
• Historically, Other Operating Expenses has averaged -$1.3 million across 5 years, with a median of -$30000.0 in 2026.
• The sharpest annual moves came in 2024 and 2025: Other Operating Expenses sank 1276.07% in 2024, then soared 422.9% in 2025.
• Over 5 years, Other Operating Expenses stood at $758569.0 in 2022, then slumped by 530.78% to -$3.3 million in 2023, then sank by 97.93% to -$6.5 million in 2024, then jumped by 422.9% to $20.9 million in 2025, then sank by 100.14% to -$30000.0 in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered -$30000.0, -$6.6 million, and $20.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.